Karl S. Dahlquist, Chief Legal Officer of AtriCure Inc., sold 9,370 shares of common stock on August 24, 2026, for a total of $458,099. Individual sale prices ranged from $48.88 to $48.89 per share, according to regulatory filings.
The transaction follows a 54% increase in AtriCure's stock price over the past six months. As of the filing, Dahlquist directly held 87,319 shares of the company's common stock. AtriCure's shares reached a 52-week high of $49.88 earlier in the month.
AtriCure reported adjusted earnings of $0.18 per share for the second quarter of 2026, exceeding analyst expectations of a $0.01 loss per share. Revenue for the quarter totaled $153.6 million, surpassing the anticipated $151.84 million. The company's P/E ratio stands at 229, with InvestingPro analysis indicating the stock appears overvalued relative to its fair value.
BTIG maintained a Buy rating on AtriCure and raised its price target to $55 from $45. The upgrade cited a new quality metric from the Society of Thoracic Surgeons that could drive adoption of AtriCure's Open Ablation products.
